News: CytRx Corp (CYTR.PH)

CYTR.PH on Philadelphia Stock Exchange

3.25USD
17 Apr 2014
Price Change (% chg)

$0.24 (+7.97%)
Prev Close
$3.01
Open
$2.96
Day's High
$3.25
Day's Low
$2.96
Volume
7,409
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks
Select another date:

Tue, Jan 21 2014

BRIEF-Cytrx up 8.5 percent premarket

NEW YORK, Jan 21 - CytRx Corp : * Up 8.5 percent to $7.64 premarket; gets FDA OK to extend aldoxorubicin dosing cycles in late-stage trial for soft tissue sarcomas

MARKET PULSE-Hilton, Faceboook, Cytrx, Genvec, Cisco, ARC Group

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell for a third day on Thursday amid uncertainty over how soon the Federal Reserve will trim its market-friendly stimulus program. The Dow Jones industrial average was down 0.63 percent at 15,744.05, the S&P 500 was down 0.29 percent at 1,777.12 and the Nasdaq Composite was down 0.01 per

CytRx's cancer treatment meets main goal, shares soar

- CytRx Corp said its experimental cancer treatment improved survival rates in untreated soft tissue sarcoma patients without the disease progressing, compared with standard chemotherapy alone, sending the company's shares up as much as 83 percent.

UPDATE 1-CytRx's cancer treatment meets main goal, shares soar

(Adds CEO and analyst comments, background, share movement)

CytRx's cancer drug meets main goal, shares soar

Dec 11 - CytRx Corp said its experimental cancer drug improved survival rates in soft tissue sarcoma patients without the disease progressing, compared to chemotherapy alone, sending its shares up 75 percent before the bell.

BRIEF-Cytrx up 25.5 percent premarket after phase 2b clinical trial results

NEW YORK, Dec 11 - CytRx Corp : * Up 25.5 percent to $3 in premarket after phase 2b clinical trial results of aldoxorubicin

Select another date:
Search Stocks